Indian scientists have developed an experimental cancer drug called RK-251 that is designed to activate mainly inside tumour cells, according to reports from The Indian Express and the Department of Science and Technology (DST). The drug is being described as a potential future alternative to chemotherapy.
The Indian Express reports that RK-251 is a “smart” drug, meaning it is engineered to distinguish between cancerous and healthy tissue. Unlike conventional chemotherapy, which can damage healthy cells alongside malignant ones, RK-251 is intended to spare normal cells while concentrating its effect on tumours. The DST, which announced the development, said the drug could eventually replace chemotherapy as a standard treatment.
News On AIR and DD News also covered the announcement, noting that the drug was developed by Indian researchers. The reports do not specify which institution or team created RK-251, nor do they give details on clinical trial timelines or regulatory approval. The drug remains experimental at this stage.
The concept behind RK-251 is not entirely new — targeted cancer therapies have been in use for years — but the claim that it could fully replace chemotherapy is significant. Chemotherapy remains a backbone of cancer treatment worldwide, despite its harsh side effects. A drug that selectively attacks cancer cells while leaving healthy ones intact would be a major step forward, if the early results hold up in human trials.
What to watch next is whether RK-251 moves from the lab into clinical testing, and whether independent studies confirm the safety and efficacy that Indian officials have suggested.
